RxDoctor Payments Data

Sheeja Francis, MD

Rheumatology · Ann Arbor, MINPI 1578680195

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $15,520 of the $22,661 with a category attached, or 68.5%. 44 manufacturers reported payments, led by Johnson & Johnson at 49.5% of the total. Reporting peaked in 2020 at $9,427 and has fallen 62.4% since, to $3,540 in 2025.

$22,661in general payments, 2019–2025

Across 219 payments — averaging $103.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$11K
  • Gilead$5K
  • Janssen Scientific Affairs, LLC$3K
  • AbbVie$629
  • Amgen$557
  • AstraZeneca$342
  • plus $3K from 38 others

What the payments were for

  • Consulting fees$15,52068%
  • Travel & lodging$1,9659%
  • Food & beverage$4,94922%
  • Education$2271%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,661 in reported general payments places this provider in the 85th percentile of 195 rheumatology providers in Michigan.

See all rheumatology providers in Michigan

Medicare billing

Part B allowed, 2024
$414,094
Medicare patients
280
Services billed
25,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EnbrelEtanercept72$562,841
Enbrel SureclickEtanercept34$416,977
Orencia ClickjectAbatacept39$262,591
Actemra ActpenTocilizumab48$239,798
KevzaraSarilumab44$185,507
RinvoqUpadacitinib19$168,360
OrenciaAbatacept24$166,837
Humira(Cf) PenAdalimumab18$119,628
TymlosAbaloparatide20$84,403
Teriparatide11$66,364
BenlystaBelimumab11$54,575
ActemraTocilizumab15$39,179
Evenity (2 Syringes)Romosozumab-Aqqg13$31,939
Hydroxychloroquine Sulfate556$26,469
MethotrexateMethotrexate Sodium263$9,968

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Evenity (2 Syringes)$557$594,78085 claims
SanofiKevzara$46$185,50744 claims
AbbVieRinvoq$629$168,36019 claims
E.r. Squibb & Sons, L.L.C.Orencia$92$166,83724 claims
Radius Health, Inc.Tymlos$19$84,40320 claims
GSKBenlysta$119$54,57511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 195 rheumatology providers in Michigan.

Other rheumatology in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →